Jeffrey S Berger1, Joseph A Ladapo2. 1. Department of Medicine, Division of Cardiology, Department of Surgery, Division of Vascular Surgery, New York University School of Medicine, New York, New York. Electronic address: Jeffrey.berger@nyumc.org. 2. Department of Medicine, Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: JLadapo@mednet.ucla.edu.
Abstract
BACKGROUND: Little is known about patterns of medication use and lifestyle counseling in patients with peripheral artery disease (PAD) in the United States. OBJECTIVES: The authors sought to evaluate trends in both medical therapy and lifestyle counseling for PAD patients in the United States from 2005 through 2012. METHODS: Data from 1,982 outpatient visits among patients with PAD were obtained from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, a nationally representative assessment of office-based and hospital outpatient department practice. Trends in the proportion of visits with medication use (antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and cilostazol) and lifestyle counseling (exercise or diet counseling and smoking cessation) were evaluated. RESULTS: Over the 8-year period, the average annual number of ambulatory visits in the United States for PAD was 3,883,665. Across all visits, mean age was 69.2 years, 51.8% were female, and 56.6% were non-Hispanic white. Comorbid coronary artery disease (CAD) was present in 24.3% of visits. Medication use for cardiovascular prevention and symptoms of claudication was low: any antiplatelet therapy in 35.7% (standard error [SE]: 2.7%), statin in 33.1% (SE: 2.4%), ACEI/ARB in 28.4% (SE: 2.0%), and cilostazol in 4.7% (SE: 1.0%) of visits. Exercise or diet counseling was used in 22% (SE: 2.3%) of visits. Among current smokers with PAD, smoking cessation counseling or medication was used in 35.8% (SE: 4.6%) of visits. There was no significant change in medication use or lifestyle counseling over time. Compared with visits for patients with PAD alone, comorbid PAD and CAD were more likely to be prescribed antiplatelet therapy (odds ratio [OR]: 2.6; 95% confidence interval [CI]: 1.8 to 3.9), statins (OR: 2.6; 95% CI: 1.8 to 3.9), ACEI/ARB (OR: 2.6; 95% CI: 1.8 to 3.9), and smoking cessation counseling (OR: 4.4; 95% CI: 2.0 to 9.6). CONCLUSIONS: The use of guideline-recommended therapies in patients with PAD was much lower than expected, which highlights an opportunity to improve the quality of care in these high-risk patients.
BACKGROUND: Little is known about patterns of medication use and lifestyle counseling in patients with peripheral artery disease (PAD) in the United States. OBJECTIVES: The authors sought to evaluate trends in both medical therapy and lifestyle counseling for PAD patients in the United States from 2005 through 2012. METHODS: Data from 1,982 outpatient visits among patients with PAD were obtained from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, a nationally representative assessment of office-based and hospital outpatient department practice. Trends in the proportion of visits with medication use (antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and cilostazol) and lifestyle counseling (exercise or diet counseling and smoking cessation) were evaluated. RESULTS: Over the 8-year period, the average annual number of ambulatory visits in the United States for PAD was 3,883,665. Across all visits, mean age was 69.2 years, 51.8% were female, and 56.6% were non-Hispanic white. Comorbid coronary artery disease (CAD) was present in 24.3% of visits. Medication use for cardiovascular prevention and symptoms of claudication was low: any antiplatelet therapy in 35.7% (standard error [SE]: 2.7%), statin in 33.1% (SE: 2.4%), ACEI/ARB in 28.4% (SE: 2.0%), and cilostazol in 4.7% (SE: 1.0%) of visits. Exercise or diet counseling was used in 22% (SE: 2.3%) of visits. Among current smokers with PAD, smoking cessation counseling or medication was used in 35.8% (SE: 4.6%) of visits. There was no significant change in medication use or lifestyle counseling over time. Compared with visits for patients with PAD alone, comorbid PAD and CAD were more likely to be prescribed antiplatelet therapy (odds ratio [OR]: 2.6; 95% confidence interval [CI]: 1.8 to 3.9), statins (OR: 2.6; 95% CI: 1.8 to 3.9), ACEI/ARB (OR: 2.6; 95% CI: 1.8 to 3.9), and smoking cessation counseling (OR: 4.4; 95% CI: 2.0 to 9.6). CONCLUSIONS: The use of guideline-recommended therapies in patients with PAD was much lower than expected, which highlights an opportunity to improve the quality of care in these high-risk patients.
Authors: Alan T Hirsch; Matthew A Allison; Antoinette S Gomes; Matthew A Corriere; Sue Duval; Abby G Ershow; William R Hiatt; Richard H Karas; Marge B Lovell; Mary M McDermott; Donna M Mendes; Nancy A Nussmeier; Diane Treat-Jacobson Journal: Circulation Date: 2012-02-15 Impact factor: 29.690
Authors: Patrice P Cacoub; Uwe Zeymer; Tobias Limbourg; Iris Baumgartner; Don Poldermans; Joachim Röther; Deepak L Bhatt; Philippe Gabriel Steg Journal: Heart Date: 2011-02-25 Impact factor: 5.994
Authors: Marie-France Hivert; Ross Arena; Daniel E Forman; Penny M Kris-Etherton; Patrick E McBride; Russell R Pate; Bonnie Spring; Jennifer Trilk; Linda V Van Horn; William E Kraus Journal: Circulation Date: 2016-09-06 Impact factor: 29.690
Authors: Sumeet Subherwal; Manesh R Patel; Lars Kober; Eric D Peterson; Deepak L Bhatt; Gunnar H Gislason; Anne-Marie Schjerning Olsen; William S Jones; Christian Torp-Pedersen; Emil L Fosbol Journal: Eur J Prev Cardiol Date: 2014-01-07 Impact factor: 7.804
Authors: F Gerald R Fowkes; Diana Rudan; Igor Rudan; Victor Aboyans; Julie O Denenberg; Mary M McDermott; Paul E Norman; Uchechukwe K A Sampson; Linda J Williams; George A Mensah; Michael H Criqui Journal: Lancet Date: 2013-08-01 Impact factor: 79.321
Authors: Nazir Savji; Caron B Rockman; Adam H Skolnick; Yu Guo; Mark A Adelman; Thomas Riles; Jeffrey S Berger Journal: J Am Coll Cardiol Date: 2013-04-02 Impact factor: 24.094
Authors: Ehrin J Armstrong; Debbie C Chen; Gregory G Westin; Satinder Singh; Caroline E McCoach; Heejung Bang; Khung-Keong Yeo; David Anderson; Ezra A Amsterdam; John R Laird Journal: J Am Heart Assoc Date: 2014-04-10 Impact factor: 5.501
Authors: Tanya Wilcox; Jonathan D Newman; Thomas S Maldonado; Caron Rockman; Jeffrey S Berger Journal: Atherosclerosis Date: 2018-04-30 Impact factor: 5.162
Authors: Anna K Krawisz; Sahana Natesan; Rishi K Wadhera; Siyan Chen; Yang Song; Robert W Yeh; Michael R Jaff; Jay Giri; Howard Julien; Eric A Secemsky Journal: Circulation Date: 2022-06-13 Impact factor: 39.918
Authors: Yevgeniy Khariton; Krishna K Patel; Paul S Chan; Yashashwi Pokharel; Jingyan Wang; John A Spertus; David M Safley; William R Hiatt; Kim G Smolderen Journal: Clin Cardiol Date: 2018-10-19 Impact factor: 2.882
Authors: Adelaide M Arruda-Olson; Homam Moussa Pacha; Naveed Afzal; Sara Abram; Bradley R Lewis; Iyad Isseh; Raad Haddad; Christopher G Scott; Kent Bailey; Hongfang Liu; Thom W Rooke; Iftikhar J Kullo Journal: Vasc Med Date: 2017-10-25 Impact factor: 3.239
Authors: Neil A Kelly; Orysya Soroka; Chukwuma Onyebeke; Laura C Pinheiro; Samprit Banerjee; Monika M Safford; Parag Goyal Journal: J Am Geriatr Soc Date: 2021-10-25 Impact factor: 7.538
Authors: Rebecca Robbins; Azizi Seixas; Girardin Jean-Louis; Sairam Parthasarathy; David M Rapoport; Gbenga Ogedegbe; Joseph A Ladapo Journal: PLoS One Date: 2018-05-23 Impact factor: 3.240